A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med 2020 Jun 16;172(12):819-821
Date
04/01/2020Pubmed ID
32227189Pubmed Central ID
PMC7138335DOI
10.7326/M20-1223Scopus ID
2-s2.0-85083710801 (requires institutional sign-in at Scopus site) 163 CitationsAbstract
Hydroxychloroquine, an essential treatment for many patients with rheumatologic conditions, has recently garnered widespread attention as a potential treatment for COVID-19 infection. The authors appraise the study generating this interest and highlight the potential consequences of rapid dissemination of overinterpreted data, particularly for people with conditions for which hydroxychloroquine has demonstrated benefits in preventing organ damage and life-threatening disease flares.
Author List
Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, Graef ER, Korsten P, Sattui SE, Sirotich E, Ugarte-Gil MF, Webb K, Grainger R, COVID-19 Global Rheumatology AllianceAuthor
Michael Putman MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antiviral AgentsAzithromycin
Betacoronavirus
Clinical Trials as Topic
Coronavirus Infections
Humans
Hydroxychloroquine
Information Dissemination
Mass Media
Pandemics
Pneumonia, Viral
Research Design